Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.004 AUD | +33.33% | 0.00% | +14.29% |
Mar. 25 | Avecho Biotechnology Begins Patient Recruitment for Phase Three Anti-Insomnia Drug Trial | MT |
Mar. 14 | Avecho to Push Forward with Phase III Trial of Anti-Insomnia Drug | MT |
Sales 2022 | 1.13M 745K | Sales 2023 | 474K 313K | Capitalization | 11.09M 7.32M |
---|---|---|---|---|---|
Net income 2022 | -2M -1.32M | Net income 2023 | -3M -1.98M | EV / Sales 2022 | 23.3 x |
Net cash position 2022 | 1.22M 807K | Net cash position 2023 | 5.33M 3.52M | EV / Sales 2023 | 12.2 x |
P/E ratio 2022 |
-11.5
x | P/E ratio 2023 |
-2.31
x | Employees | 15 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 65.6% |
1 day | +33.33% | ||
1 month | -11.11% | ||
3 months | +33.33% | ||
6 months | +14.29% | ||
Current year | +14.29% |
Managers | Title | Age | Since |
---|---|---|---|
Paul David Gavin
CEO | Chief Executive Officer | - | 01-12-31 |
Melanie Leydin
DFI | Director of Finance/CFO | 51 | 18-12-27 |
Roksan Libinaki
COO | Chief Operating Officer | - | 00-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Ross Murdoch
BRD | Director/Board Member | - | 15-01-13 |
Director/Board Member | 60 | 20-01-12 | |
Gregory Collier
CHM | Chairman | - | 15-04-12 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-13 | 0.004 | +33.33% | 985 380 |
24-05-10 | 0.003 | -25.00% | 954,770 |
24-05-09 | 0.004 | 0.00% | 2,730,195 |
24-05-08 | 0.004 | 0.00% | 5,000,145 |
24-05-06 | 0.004 | 0.00% | 512,286 |
Delayed Quote Australian S.E., May 13, 2024 at 02:10 am EDT
More quotes1st Jan change | Capi. | |
---|---|---|
+14.29% | 6.28M | |
+17.96% | 44.96B | |
+1.17% | 42.65B | |
+47.02% | 41.85B | |
-4.27% | 29.04B | |
+11.42% | 26.08B | |
-21.39% | 19.03B | |
+4.86% | 12.75B | |
+27.29% | 12.06B | |
-3.50% | 11.75B |
- Stock Market
- Equities
- AVE Stock